DAVID L HEI MD NPI 1851368476

NPI Details

David L Hei, MD is a medical oncology internal medicine in Melbourne, FL with 33 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. David L Hei, MD NPI is 1851368476. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE
Graduation Year:1993

The provider's business location address is:

1130 HICKORY ST
MELBOURNE, FL
ZIP 32901-973
Phone: (321) 361-5549
Fax: (321) 952-6179

The NPI 1851368476 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS:J0129)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Red blood cells, leukocytes reduced, each unit (HCPCS:P9016)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Transfusion of blood or blood products (HCPCS:36430)
• Injection of drug or substance into vein (HCPCS:96374)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Drawing of blood for a medical problem (HCPCS:99195)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)

The enumeration date for this NPI number is 3/2/2006 and was last updated on 5/17/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.